Is there a secret to longevity? This health expert says 1,000% yes
In the era of social media, post-COVID, and with mental health at the forefront, a shift is taking […]
FDA approves the first-ever oral pill for postpartum depression
Tired Mother Suffering from experiencing postnatal depression.
Zurzuvae, recently approved by the US Food and Drug Administration (FDA), promises a new chapter in treating postpartum depression (PPD), a debilitating mental health challenge affecting many new mothers.
Developed in collaboration by Biogen and Sage Therapeutics, Zurzuvae underwent a series of rigorous trials. Women with PPD, a condition manifesting after childbirth or during late pregnancy and known to cause cognitive issues and even suicidal ideation, were the primary participants.
Prior to this, the FDA had only sanctioned an IV-based treatment method for PPD, administered under medical supervision. In contrast, Zurzuvae, with its oral formulation, is anticipated to hit the market later this year, making treatment more accessible.
Dr. Tiffany R. Farchione, the esteemed director of the Division of Psychiatry in the FDA’s Centre for Drug Evaluation and Research, highlighted the severity of PPD. She remarked, “Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness — even, in severe cases, thoughts of harming themselves or their child”.
However, potential users should be aware of Zurzuvae’s side effects, which can include symptoms like drowsiness, fatigue, dizziness, urinary infections, and heightened fatigue. More alarmingly, there is the risk of the drug inducing suicidal tendencies.
In-depth studies on Zurzuvae showed promising outcomes. Patients exhibited discernible improvement in depressive symptoms, as gauged by the comprehensive 17-item Hamilton depression rating scale, distinguishing them from placebo participants.
According to FDA’s guidelines, the effective dosage stands at 50mg daily for a fortnight, best taken during dinner with a fatty meal.
Globally, PPD remains a significant concern, impacting 10-15% of women. Research from 2012 highlighted that, in Qatar alone, PPD affected 17.6% of women. Sadly, a vast majority, nearly 50%, remain undiagnosed despite clear symptoms.
However, there is a silver lining. An impressive 80% of women combatting PPD eventually return to their pre-depression selves, underscoring the vitality of consistent psychological support during recovery.
